Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Myriad Genetics, Inc. MYGN
$17.73
+$0.17 (0.94%)
На 18:00, 12 мая 2023
+26.90%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1433740416.00000000
-
week52high
28.18
-
week52low
13.92
-
Revenue
678400000
-
P/E TTM
-14
-
Beta
1.63651100
-
EPS
-1.40000000
-
Last Dividend
3.50000000
-
Next Earnings Date
02 авг 2023 г. в 12:30
Описание компании
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Market Perform | Market Perform | 05 авг 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 05 мая 2022 г. |
| Goldman Sachs | Sell | Sell | 19 апр 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 03 ноя 2021 г. |
| Raymond James | Market Perform | 15 июн 2021 г. | |
| Stephens & Co. | Equal-Weight | 06 окт 2022 г. | |
| SVB Leerink | Market Perform | Market Perform | 02 ноя 2022 г. |
| Raymond James | Outperform | Market Perform | 18 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Riggsbee Richard Bryan | D | 364107 | 9400 | 20 янв 2023 г. |
| Riggsbee Richard Bryan | D | 373507 | 600 | 18 янв 2023 г. |
| Lambert Nicole | D | 228404 | 853 | 01 янв 2023 г. |
| Muzzey Dale | D | 42712 | 302 | 01 янв 2023 г. |
| Riggsbee Richard Bryan | D | 374107 | 20000 | 27 дек 2022 г. |
| BISARO PAUL | A | 16875 | 16875 | 31 окт 2022 г. |
| Wong Pamela | D | 51860 | 1972 | 18 окт 2022 г. |
| Wong Pamela | D | 53832 | 1346 | 18 окт 2022 г. |
| Muzzey Dale | D | 43014 | 309 | 09 окт 2022 г. |
| Haas Kevin Richard | D | 85295 | 1721 | 09 окт 2022 г. |
Новостная лента
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
03 мая 2023 г. в 19:02
Myriad Genetics (MYGN) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.03 per share a year ago.
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
GlobeNewsWire
26 апр 2023 г. в 16:05
SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Wednesday May 3, 2023 at 4:30 p.m. ET. The company's quarterly earnings will be released the same day after the market closes.
Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing
Zacks Investment Research
19 апр 2023 г. в 09:55
Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.
Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access
Zacks Investment Research
03 мар 2023 г. в 12:48
Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.
Larry Robbins' Firm Boosts 2 Health Care Stocks
GuruFocus
02 мар 2023 г. в 17:35
Glenview Capital Management, the firm founded by Larry Robbins (Trades, Portfolio), disclosed in regulatory filings that it boosted during February its holdings in Myriad Genetics Inc. ( MYGN , Financial) and Butterfly Network Inc. ( BFLY , Financial) according to GuruFocus Real-Time Picks, a Premium feature.